14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $221.55 $250.89 Monday, 22nd Apr 2024 UTHR stock ended at $234.06. This is 1.63% less than the trading day before Friday, 19th Apr 2024. During the day the stock fluctuated 2.04% from a day low at $233.77 to a day high of $238.55.
90 days $208.62 $250.89
52 weeks $204.44 $261.48

Historical United Therapeutics Corporation prices

Date Open High Low Close Volume
Apr 22, 2024 $238.20 $238.55 $233.77 $234.06 536 926
Apr 19, 2024 $237.47 $238.34 $234.86 $237.93 361 856
Apr 18, 2024 $234.67 $240.74 $234.31 $236.93 441 657
Apr 17, 2024 $232.94 $237.64 $232.94 $235.31 356 498
Apr 16, 2024 $234.11 $234.11 $230.39 $231.78 487 113
Apr 15, 2024 $233.21 $237.93 $232.79 $235.08 322 042
Apr 12, 2024 $237.98 $239.32 $232.41 $232.59 416 423
Apr 11, 2024 $239.51 $241.37 $236.86 $237.24 618 605
Apr 10, 2024 $235.42 $238.38 $232.42 $237.79 410 595
Apr 09, 2024 $236.58 $238.04 $235.25 $237.04 399 155
Apr 08, 2024 $232.04 $239.81 $232.04 $236.96 434 423
Apr 05, 2024 $233.15 $237.27 $230.91 $233.56 409 039
Apr 04, 2024 $231.77 $235.01 $229.72 $233.93 517 028
Apr 03, 2024 $228.36 $232.54 $227.75 $231.20 387 243
Apr 02, 2024 $228.40 $231.02 $225.62 $228.58 533 457
Apr 01, 2024 $228.03 $230.27 $221.55 $228.26 783 579
Mar 28, 2024 $243.57 $243.57 $229.14 $229.72 1 114 533
Mar 27, 2024 $245.26 $249.67 $237.46 $243.27 626 139
Mar 26, 2024 $244.67 $250.89 $244.67 $247.86 534 056
Mar 25, 2024 $247.86 $249.19 $238.84 $244.26 739 386
Mar 22, 2024 $237.82 $238.68 $234.02 $237.90 293 356
Mar 21, 2024 $237.06 $237.84 $233.79 $236.93 296 584
Mar 20, 2024 $238.28 $238.56 $233.22 $236.73 438 698
Mar 19, 2024 $235.00 $239.65 $232.42 $239.40 508 115
Mar 18, 2024 $235.91 $237.00 $229.72 $233.97 431 435
Click to get the best stock tips daily for free!

About United Therapeutics Corporation

United Therapeutics United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin a... UTHR Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT